ATC Group: L04AA41 Imlifidase

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AA41 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AA Selective immunosuppressants
5 L04AA41

Active ingredients in L04AA41

Active Ingredient Description
Imlifidase

Imlifidase is a cysteine protease derived from the immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that cleaves the heavy chains of all human IgG subclasses but no other immunoglobulins. The cleavage of IgG leads to elimination of Fc-dependent effector functions, including CDC and antibody-dependent cell-mediated cytotoxicity (ADCC). By cleaving all IgG, imlifidase reduces the level of DSA, thus enabling transplantation.

Related product monographs

Title Information Source Document Type  
IDEFIRIX Powder for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Estonia (EE)

Finland (FI)

Ireland (IE)

Israel (IL)

Italy (IT)

Lithuania (LT)

Poland (PL)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.